Innovative trial design puts patients first in CBD epilepsy research

This study describes the development of the PACIFIC (PAtient-Centric epilepsy clinical trIal model For Improved health outcomes using Cannabidiol) trial, a groundbreaking methodological framework designed to address the significant challenges of conducting clinical research in rare epilepsy syndromes. Traditional clinical trial designs have struggled with rare epilepsies due to small patient populations, heterogeneous disease presentations, and a lack of outcome measures that truly matter to patients and families. The PACIFIC study aims to revolutionize this approach by incorporating patient-centered design principles, including decentralized trial models that reduce patient burden, adaptive trial designs that can adjust based on emerging data, and participatory approaches that involve patients and caregivers in shaping research priorities.

The methodology represents a significant shift toward more ethical and practical clinical trial conduct in rare disease populations, particularly for evaluating cannabidiol (CBD) as a treatment option. By embracing innovative trial designs, the PACIFIC framework addresses critical gaps in how we study cannabinoid therapies for vulnerable populations with rare epilepsies. This patient-first approach ensures that clinical outcomes measured in trials actually reflect real-world improvements in quality of life, rather than just traditional clinical endpoints that may not capture what matters most to families managing rare epilepsy syndromes. The framework has potential applications beyond epilepsy, offering a blueprint for studying cannabis-based medicines in other rare and complex neurological conditions.